ReviewAging clinical and experimental research2024
Acetyl-cholinesterase-inhibitors reconsidered. A narrative review of post-marketing studies on Alzheimer's disease.
Review in Aging clinical and experimental research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia.GeroScience · 2026Article
- A Fluorescence-Based Acetylcholinesterase Inhibition Assay for Bioactivity-Guided Identification of Neuroactive Protoberberine Alkaloids fromMolecules (Basel, Switzerland) · 2026Article
- Rethinking dementia prevention: what the new WHO guidelines get right (and what they left behind).Aging clinical and experimental research · 2026Article
- Flavonoids From Fumana juniperina (Lag. ex Dunal) Aerial Parts: Chemical Characterization, Antioxidant, and Anticholinesterase Activities Supported by In Silico Analysis.Chemistry & biodiversity · 2026Article
- A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease-Like Non-Human Primate Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bridging the gaps in alzheimer's disease: a comprehensive review of current and emerging therapies.Inflammopharmacology · 2026Review
- Why acetylcholinesterase inhibitors should be considered disease-modifying drugs for Alzheimer's disease?Aging clinical and experimental research · 2026Review
- Article
- Long-Term Effect of Acetylcholinesterase Inhibitors on Behavioral and Psychological Symptoms of Dementia.International journal of geriatric psychiatry · 2026Article
- Multiscale mechanistic modeling for the rational design of novel dual-target candidates against acetylcholinesterase and NADPH oxidase: an advanced computational study.Frontiers in chemistry · 2026Article
- Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trials.Systematic reviews · 2025Article
- The impact of dual-tasking on mnestic performance in normal ageing.Scientific reports · 2025Article
- Advances in the Exploration of Coordination Complexes of Vanadium in the Realm of Alzheimer's Disease: A Mini Review.Molecules (Basel, Switzerland) · 2025Review
- Article
- Evaluation of the Alterations in Central Cholinergic Neurotransmission in Aging and Amyloid Precursor Protein Knock-In Mice.Journal of neurochemistry · 2025Article
- Determination of optimum extract conditions and evaluation of biological activity potential of Salvia cilicica Boiss.Scientific reports · 2025Article
- Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- A Novel Tetrahydroacridine Derivative with Potent Acetylcholinesterase Inhibitory Properties and Dissociative Capability against Aβ42 Fibrils Confirmed by In Vitro Studies.International journal of molecular sciences · 2024Article
- Synthesis of novel hybrids of 1,2,3-triazoles-hydrazone: targeting cholinesterases and Alzheimer's related genes.Future medicinal chemistry · 2024Article
- Persistence with antidementia therapy in Germany: A retrospective cohort study of 567,815 patients.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The real efficacy of Acetyl-cholinesterase-inhibitors (AChEI) has been questioned. In this narrative review we evaluated their effect on cognitive decline, measured by Mini Mental State Examination (MMSE), and on total mortality rates in patients with Alzheimer's disease (AD) recruited into post-marketing open/non-randomized/retrospective studies. In AD patients treated with AChEI, the mean MMSE loss ranged from 0.2 to 1.37 points/years, compared with 1.07-3.4 points/years in non-treated patients. Six studies also reported data about survival; a reduction in total mortality relative risk between 27% and 42% was observed, over a period of 2-8 years. The type of studies and the use of MMSE to assess cognitive decline, may have introduced several biases. However, the clinical effects of AChEI seem to be of the same order of magnitude as the drugs currently used in most common chronic disorders, as regards progression of the disease and total mortality. In the absence of long-term randomized trials on "standard" unselected AD outpatients, open/retrospective studies and health databases represent the best available evidence on the possible effect of AChEI in the real-word setting. Our data support the clinical benefit of AChEI in older patients affected by AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.